Drug Trial Radar · NCT07140328
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 24, 2025
Primary completion
Jul 10, 2025
Study completion Aug 2026
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.
Conditions
- Chronic Obstructive Lung Disease (COLD)
Interventions
HSK39004 Dry Powder Inhaler -0.75mg BIDDrug
HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day; And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ;
HSK39004 Dry Powder Inhaler -1.5mg BIDDrug
HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day; And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ;
HSK39004 Inhalation Suspension -3mg BIDDrug
HSK39004 Inhalation Suspension: Inhale through the mouth, 3mg each time, twice a day; And HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ;
HSK39004 PlaceboDrug
HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ; And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ;
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. The ΔFEV1 AUC0-12h after the 4th week administration (the area under the curve representing the change in FEV1 from baseline to 12 hours after administration)Time frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial People's Hospital
Nanchang, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.